New drug cocktail targets deadly bowel cancer mutation

NCT ID NCT06008119

Recruiting now Disease control Sponsor: Shanghai Kechow Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial is testing whether a combination of two targeted drugs, tunlametinib and vemurafenib, can help people with a specific genetic mutation (BRAF V600E) in metastatic colorectal cancer. About 165 participants will be randomly assigned to receive either the drug combo or standard chemotherapy. The main goal is to see if the combo slows cancer growth better than current treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tunlametinib plus vemurafenib
What this could lead to: If successful, this combination could offer a new targeted treatment option for people with a specific genetic subtype of advanced colorectal cancer, potentially slowing disease progression.
What could go wrong: This is an early-stage Phase 3 trial with only 165 participants. The combination may not prove more effective than standard chemotherapy, and side effects from the two drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER METASTATIC

Contacts and locations

Locations

Beijing Oncology Hospital
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.